Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics managing director buys more shares on-market

A number of board members have purchased shares in the company in 2019 to date.
three empty board seats
The shares were purchased at an average price of 15.5 cents each

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills has purchased 65,000 shares in the company via on-market trades.

The $10,075 parcel of shares increases Mills’ total holding in the company to over 7.57 million shares.

READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January this year.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.

CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

muffins and cannabis
November 29 2018
Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time
cannabis plant
December 14 2018
The Vancouver-based cannabis group services medical and recreational cannabis markets in Canada and internationally
windmill
May 07 2019
TGOD has been busy building out its facilities in Ontario, Quebec, and Jamaica and expects to reach combined production of 219,000 kilograms of cannabis around 2021
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use